Header image

UKMRA / UKMS Session: Prognostic risk factors and Bispecific Antibodies for Multiple Myeloma - how to bring them into practice

Track 3
Tuesday, April 30, 2024
2:15 PM - 3:45 PM
Room 3A


Prognostic tests and treatments for multiple myeloma are rapidly evolving with technological advances. This session addresses the real world challenge of how best to integrate such advances into practice. Dr Martin Kaiser, Consultant Haematologist at the Royal Marsden Hospital will provide an update to prognostic factors used for myeloma with an overview of cytogenetic risk stratification and the use of diagnostic platforms such as gene expression profiling as well as other biomarkers. Prof Saad Usmani, Chief of Myeloma Service at MSKCC, New York and Chair of the US Alliance co-operative group will describe how he uses bispecific T cell engagers in routine practice, how to manage the toxicity profile and where the future lies. Dr Frances Seymour, Consultant Haematologist at Leeds Teaching Hospitals will describe how T cell immunotherapies can be implemented in the UK drawing on learnings from other haematological cancers. There will then be a discussion chaired by Dr Rakesh Popat, Consultant Haematologist at University College London and Dr Ceri Bygrave, Consultant Haematologist at University Hospital of Wales on how we an incorporate these new developments into routine UK practice to improve outcomes for our patients.


Dr. Martin Kaiser
Consultant Haematologist
The Royal Marsden Hospital

Towards precision diagnostics for myeloma patients

Agenda Item Image
Dr. Saad Usmani
Chief Of Myeloma Service

How I use bispecific antibodies for multiple myeloma

Agenda Item Image
Dr. Frances Seymour
Consultant Haematologist
Leeds Teaching Hospitals NHS Trust

T cell immunotherapy for myeloma in the UK – are we ready for it?

Agenda Item Image
Dr Ceri Bygrave
Consultant Haematologist
University Hospital of Wales

Bispecific Antibody Treatment for Myeloma: how to implement new advances into routine practice


Agenda Item Image
Rakesh Popat
Consultant Haematologist
University College London Hospitals